Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

RG, Wunderink; EJ, Giamarellos-Bourboulis; G, Rahav; AJ, Mathers; M, Bassetti; J, Vazquez; OA, Cornely; J, Solomkin; T, Bhowmick; J, Bishara; GL, Daikos; T, Felton; MJL, Furst; EJ, Kwak; F, Menichetti; I, Oren; EL, Alexander; D, Griffith; O, Lomovskaya; J, Loutit; S, Zhang; MN, Dudley; KS, Kaye

doi:10.1007/s40121-018-0214-1

Public

Effect and Safety of Meropenem-Vaborbactam versus Best-Available Therapy in Patients with Carbapenem-Resistant Enterobacteriaceae Infections: The TANGO II Randomized Clinical Trial.

Published in Infectious diseases and therapy • Oct 1, 2018

Authors:

Wunderink RG

Giamarellos-Bourboulis EJ

Rahav G

Abstract

<h4>Introduction</h4>Treatment options for carbapenem-resistant Enterobacteriaceae (CRE) infections are limited and CRE infections remain associated with high clinical failure and mortality rates, particularly in vulnerable patient populations. A Phase 3, multinational, open-label, randomized contro...

View

Open Access

Subject

Randomized Clinical Trial

Carbapenem-resistant Enterobacteriaceae

Meropenem–vaborbactam

Generate AI Take for this paper

Highlights, strengths & weaknesses, commercial applications, and societal impact — written for this paper on demand.

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!